Rezolute Inc
Rezolute is a clinical-stage rare disease company focused on therapies for metabolic and orphan diseases affecting glucose metabolism. The company's lead asset ersodetug is a human monoclonal antibody targeting the insulin receptor. The Phase 3 sunRIZE trial in congenital hyperinsulinism did not meet its primary endpoint (reported December 2025), and Rezolute is exploring next steps with the FDA.
Focus areas at Rezolute Inc
The clinical trials section below shows active and recruiting rare disease studies sponsored by Rezolute Inc, sourced live from ClinicalTrials.gov. Each trial includes its current recruitment status, study phase (Phase 1 through Phase 4), conditions under investigation, and the number of active trial sites. The FDA-approved drugs section lists treatments that have received U.S. Food and Drug Administration approval, with brand names, generic names, approval dates, and matched rare disease indications from the openFDA database.
Rezolute Inc is headquartered in Redwood City, United States, founded in 2010, publicly traded under the ticker symbol RZLT. The company dedicates its research and development resources exclusively to rare and orphan diseases, working to bring innovative treatments to patients with conditions that have historically had limited or no treatment options.
Rezolute Inc Drug Pipeline
Rezolute Inc has 2 active clinical trials across 1 development stage, with 1 currently recruiting participants. Clinical trials advance through phases: Phase 1 tests safety in a small group, Phase 2 evaluates effectiveness and side effects, Phase 3 confirms benefit in a larger population, and Phase 4 monitors long-term safety after FDA approval.
Note: This pipeline counts the active and recruiting trials listed on this page, from ClinicalTrials.gov. For companies that work outside rare disease, we list only trials for rare diseases we track, so the company's full pipeline may be larger.
Rezolute Inc Clinical Trials (2)
Active and recruiting clinical trials sponsored by Rezolute Inc, sourced live from ClinicalTrials.gov. Each trial card shows the study phase, current recruitment status, conditions under investigation, study locations, eligibility criteria, and a direct link to the full ClinicalTrials.gov record. You can also download a one-page PDF summary to share with your doctor.
Note: Recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator.
FDA-Approved Drugs
Rezolute Inc Trial Locations
Rezolute Inc clinical trials are running at 31 sites in 15 countries. Click any country to drill down by state, city, and individual research facility. Proximity to a trial site is one of the most important factors in deciding whether to participate.
Frequently Asked Questions About Rezolute Inc
Common questions about Rezolute Inc's rare disease programs, clinical trials, and treatments.